Ser1392
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1392  -  APC (human)

Site Information
sRCTsVSsLDsFESR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450135

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 3 ) , immunoprecipitation ( 3 ) , mass spectrometry ( 2 ) , mutation of modification site ( 3 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 3 ) , HCC1359 (pulmonary) ( 2 ) , HCC2279 (pulmonary) ( 2 ) , HCC4006 (pulmonary) ( 2 ) , NCI-H2172 (pulmonary) ( 2 ) , SW480 (intestinal) ( 3 )

Upstream Regulation
Putative in vivo kinases:
CK1E (human) ( 3 )

Downstream Regulation
Effects of modification on biological processes:
transcription, altered ( 3 )

References 

1

Schneikert J, Ruppert JG, Behrens J, Wenzel EM (2014) Different Roles for the Axin Interactions with the SAMP versus the Second Twenty Amino Acid Repeat of Adenomatous Polyposis Coli. PLoS One 9, e94413
24722208   Curated Info

2

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

3

Rubinfeld B, Tice DA, Polakis P (2001) Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilon. J Biol Chem 276, 39037-45
11487578   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.